Latest Hotspot

UK's MHRA approves CRISPR and Vertex's gene-editing treatment, CASGEVY, for Sickle Cell and Beta Thalassemia using CRISPR/Cas9

23 November 2023
3 min read

It has been announced by Vertex Pharmaceuticals Incorporated in alliance with CRISPR Therapeutics that CASGEVY™ (exagamglogene autotemcel [exa-cel]), a therapeutic intervention genetically edited using CRISPR/Cas9 technology, has successfully obtained a provisional go-ahead for marketing from the UK's Medicines and Healthcare products Regulatory Agency. This authorization brings new hope for treatment options for patients suffering from both sickle cell ailment and transfusion-reliant beta thalassemia.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

CASGEVY has received authorization to treat qualified patients aged 12 and up with SCD who are experiencing regular vas-occlusive crises or TDT, in cases where a related hematopoietic stem cell donor, with human leukocyte antigen compatibility, is not readily available. The estimation is that about 2,000 patients could benefit from CASGEVY across the UK.

"I trust this is only the beginning of many implementations of this Nobel Prize-recognized technology that can assist patients with severe diseases," commented Samarth Kulkarni, Ph.D., CRISPR Therapeutics' CEO and Chairman.

In two international clinical trials targeting SCD and TDT patients with CASGEVY, the trials reached their primary goal of patients remaining free from extreme VOCs or being transfusion independant over a span of 12 straight months. If fulfilled, such benefits are possibly thought to be lifelong. The characterization of safety for 97 patients with SCD and TDT that have been treated with CASGEVY thus far in these ongoing trials generally aligns with the myeloablative conditioning with busufan and hematopoietic stem cell transplant.

Professor Josu de la Fuente, Principal Investigator for the CLIMB-111 and CLIMB-121 studies, Professor of Practice at Imperial College London, and Consultant Haematologist for Imperial College Healthcare NHS Trust, said, "This approval provides an alternative for deserving patients awaiting novel treatments, and I eagerly anticipate patients receiving this treatment as swiftly as possible."

In the UK, the MHRA issued an Innovation Passport to exa-cel under the Innovative Licensing and Access Pathway, and Vertex is collaborating intensely with national health authorities to guarantee speedy access for deserving patients.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

低可信度描述已自动生成

According to the data provided by the Synapse Database, As of November 22, 2023, there are 36 investigational drugs for the Hemoglobins target, including 50 indications, 53 R&D institutions involved, with related clinical trials reaching 372, and as many as 4560 patents.

CASGEVY™ is also under review by the European Medicines Agency, the Saudi Food and Drug Authority, and the U.S. Food and Drug Administration (FDA). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act (PDUFA) target action dates of December 8, 2023, and March 30, 2024, respectively.

图形用户界面, 文本, 应用程序

描述已自动生成

Exploring TILT-123's R&D successes and its clinical results at the 2023 SITC
Exploring TILT-123's R&D successes and its clinical results at the 2023 SITC
23 November 2023
The 2023 SITC Congress reported that TILT-123, a T-cell inducing oncolytic virus, is safe, effective at fighting tumors, and can boost immune responses in patients with advanced solid tumors.
Read →
Carmot Therapeutics starts phase 2 trial for CT-868, a GLP-1/GIP agonist, to treat Type 1 Diabetes
Latest Hotspot
3 min read
Carmot Therapeutics starts phase 2 trial for CT-868, a GLP-1/GIP agonist, to treat Type 1 Diabetes
23 November 2023
Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.
Read →
What are CTLA4 inhibitors and how do you quickly get the latest development progress?
What are CTLA4 inhibitors and how do you quickly get the latest development progress?
23 November 2023
The first immune checkpoint inhibitor for clinical use: CTLA-4 inhibitor. However, it enhances immune function, specifically by boosting the cytotoxicity of immune cells, which often results in more adverse effects.
Read →
Biological Glossary | What is Plasmid?
Bio Sequence
2 min read
Biological Glossary | What is Plasmid?
23 November 2023
A plasmid is a small, circular, double-stranded DNA molecule that is distinct from a cell's chromosomal DNA.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.